Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 10/20 | 0.51 |
| ▸ | HTR1D | P28221 | 10/20 | 0.51 |
| ▸ | HTR1B | P28222 | 10/20 | 0.51 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176341 | 0.96 | CKS1B (0.53) | CYP2C9NCF1HTR1AHTR1DHTR1B | |
| SCHEMBL425806 | 0.87 | BACE1 (0.51) | NCF1GBA1CKS1BSKP1SKP2 | |
| SCHEMBL5379011 | 0.86 | GBA1 (0.49) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL5523102 | 0.86 | NCF1 (0.72) | NCF1GBA1CKS1BSKP1SKP2 | |
| SCHEMBL431774 | 0.85 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL428233 | 0.85 | GBA1 (0.48) | NCF1GBA1CKS1BSKP1SKP2 | |
| SCHEMBL429714 | 0.85 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL4178112 | 0.85 | NCF1 (0.59) | CYP2C9NCF1HTR1AHTR1DHTR1B | |
| SCHEMBL430252 | 0.84 | GBA1 (0.48) | HTR1AHTR1DHTR1BGBA1CKS1B | |
| SCHEMBL428076 | 0.84 | GBA1 (0.48) | NCF1GBA1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | claimed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| CN-101048414-A | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1646613-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | CYP2C9 1185/4885NCF1 4523/4885HTR1A 7/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885NCF1 1952/4885HTR1A 1/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | CYP2C9 106/4885NCF1 3681/4885HTR1A 476/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885NCF1 1952/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.